Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

43 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Exceptional early blood pressure control rates: the ACCOMPLISH trial.
Jamerson K, Bakris GL, Dahlöf B, Pitt B, Velazquez E, Gupte J, Lefkowitz M, Hester A, Shi V, Kjeldsen SE, Cushman W, Papademetriou V, Weber M; ACCOMPLISH Investigators. Jamerson K, et al. Among authors: gupte j. Blood Press. 2007;16(2):80-6. doi: 10.1080/08037050701395571. Blood Press. 2007. PMID: 17612905 Clinical Trial.
Predictors of blood pressure response to intensified and fixed combination treatment of hypertension: the ACCOMPLISH study.
Kjeldsen SE, Jamerson KA, Bakris GL, Pitt B, Dahlöf B, Velazquez EJ, Gupte J, Staikos L, Hua TA, Shi V, Hester A, Tuomilehto J, Ostergren J, Ibsen H, Weber M; Avoiding Cardiovascular events through COMbination therapy in Patients LIving with Systolic Hypertension Investigators. Kjeldsen SE, et al. Among authors: gupte j. Blood Press. 2008;17(1):7-17. doi: 10.1080/08037050801972857. Blood Press. 2008. PMID: 18568687 Clinical Trial.
Baseline characteristics in the Avoiding Cardiovascular events through Combination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial: a hypertensive population at high cardiovascular risk.
Weber MA, Bakris GL, Dahlöf B, Pitt B, Velazquez E, Gupte J, Lefkowitz M, Hester A, Shi V, Weir M, Kjeldsen S, Massie B, Nesbitt S, Ofili E, Jamerson K. Weber MA, et al. Among authors: gupte j. Blood Press. 2007;16(1):13-9. doi: 10.1080/08037050701217643. Blood Press. 2007. PMID: 17453747 Clinical Trial.
Liver-specific mitochondrial amidoxime-reducing component 1 (Mtarc1) knockdown protects the liver from diet-induced MASH in multiple mouse models.
Guo Y, Gao Z, LaGory EL, Kristin LW, Gupte J, Gong Y, Rardin MJ, Liu T, Nguyen TT, Long J, Hsu YH, Murray JK, Lade J, Jackson S, Zhang J. Guo Y, et al. Among authors: gupte j. Hepatol Commun. 2024 May 2;8(5):e0419. doi: 10.1097/HC9.0000000000000419. eCollection 2024 May 1. Hepatol Commun. 2024. PMID: 38696369 Free PMC article.
COVID-19: what is not being addressed.
Gupte J, Mitlin D. Gupte J, et al. Environ Urban. 2021 Apr;33(1):211-228. doi: 10.1177/0956247820963961. Environ Urban. 2021. PMID: 38603049 Free PMC article.
43 results